Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogenous group of
diseases and the most common subtype of non-Hodgkin lymphoma. In the past decade …

Emerging entities and molecular subgroups in large B-cell lymphomas (LBCLs) were
discussed during the 2022 European Association for Haematopathology/Society for …

Polatuzumab vedotin (Pola-V) is an antibody–drug conjugate directed to the CD79B subunit
of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola …

Clonal expansion of CD5-expressing B cells, commonly designated as monoclonal B
lymphocytosis (MBL), is a precursor condition for chronic lymphocytic leukemia (CLL). The …

Previous studies in patients with mature B-cell lymphomas (MBCL) have shown that
pathogenic TP53 aberrations are associated with inferior chemotherapeutic efficacy and …

Primary sinonasal diffuse large B-cell lymphoma (PSDLBCL) is a rare lymphoma with a
variable prognosis and a unique relapse/dissemination pattern involving the central nervous …

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary
cutaneous follicle center lymphoma with a diffuse population of large cells (PCFCL-LC) are …

Aims Primary bone diffuse large B‐cell lymphoma (PB‐DLBCL) is not recognized as a
separate entity by the current classification systems. Here we define and highlight its …

Primary bone lymphoma (PBL) is a rare neoplasm of malignant lymphoid cells presenting
with one or more bone lesions without nodal or other extranodal involvement. It accounts for …

Background Comprehensive molecular subtyping of diffuse large B‐cell lymphoma (DLBCL)
through genetic profiling has broadened our understanding of DLBCL biology. In this study …